凱萊英(002821.SZ):預計半年度淨利潤同比下降67.39%-71.54%
格隆匯7月10日丨凱萊英(002821.SZ)公佈,預計半年度淨利潤4.8億元–5.5億元,比上年同期下降67.39%-71.54%,扣非淨利潤4.3億元–4.8億元,比上年同期下降69.38%-72.57%。
2024年上半年,公司實現營業收入26.60億元-27.40億元,同比下降40.72%-42.45%,主要系去年同期交付大訂單,今年不再有相關訂單所致。報吿期內,在境內外生物醫藥融資環境持續低迷的情況下,公司營業收入剔除上年同期大訂單影響後實現微幅增長,其中,小分子CDMO業務剔除大訂單影響後同比仍保持正增長;新興業務收入主要受國內生物醫藥融資復甦不及預期,營業收入同比下降。
2024年上半年,公司實現歸屬於上市公司股東的淨利潤4.80億元-5.50億元,同比下降67.39%-71.54%,較營業收入降幅較大的主要原因為:(1)去年同期交付的大訂單毛利率較高;(2)新興業務收入下降,以及部分業務處於爬坡期,產能利用率相對較低,加上國內市場競爭較為激烈,導致新興業務毛利率較低;(3)儘管公司嚴格控制各項成本費用,但難以在短時間內實現與收入降幅保持同步調整;(4)公司着眼於未來發展,繼續保持新技術研發投入和新業務培育,研發費用規模與去年大體相當。
整體上看,儘管面臨諸多挑戰,但國際製藥行業專業分工趨勢未發生根本性改變,多肽、ADC、小核酸等藥物類別的持續活躍,都帶來了新的機遇和增量市場空間。2024年,公司加快海外佈局以及多肽產能建設,持續加大業務開拓力度,新簽訂單同比增長超過20%,且二季度較一季度環比有較大幅度增長,其中來自於歐美市場客户訂單增速超過公司整體訂單增速水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.